Literature DB >> 1326587

Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria.

P Kern1, C J Hemmer, H Gallati, S Neifer, P Kremsner, M Dietrich, F Porzsolt.   

Abstract

Elevated serum or plasma concentration of immunoreactive tumor necrosis factor (TNF) is consistently detected in patients with malaria. TNF levels correlate with high parasitemia and clinical severity but not always with outcome. Since the effects of TNF may be neutralized by soluble TNF receptors, sera of 30 nonimmune patients with malaria were analyzed before and during antimalarial therapy. High concentrations of receptors R1 (55 kDa) and R2 (75 kDa) were detected immunologically in all sera of untreated patients. Levels of immunoreactive TNF correlated closely with levels of soluble TNF R1 and R2 (r = .75 and .59, respectively). In contrast, sera lacked cytotoxic activity against target cells in the TNF bioassays. Soluble TNF receptor levels remained elevated for days after treatment. These results suggest that excessive release of TNF induced by the asexual stage of malaria parasites is controlled by a subsequent shedding of soluble TNF receptors that may bind and deactivate biologically functional TNF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1326587     DOI: 10.1093/infdis/166.4.930

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Increased levels of soluble Fas ligand in serum in Plasmodium falciparum malaria.

Authors:  P Kern; M Dietrich; C Hemmer; N Wellinghausen
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  MRP 8/14 as marker for Plasmodium falciparum-induced malaria episodes in individuals in a holoendemic area.

Authors:  G Bordmann; G Burmeister; S Saladin; H Urassa; S Mwankyusye; N Weiss; M Tanner
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

Review 3.  Cerebral malaria.

Authors:  C R Newton; T T Hien; N White
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-10       Impact factor: 10.154

4.  Soluble tumor necrosis factor alpha receptors (sTNF-Rs) in HIV-1-infected intravenous drug users: change in circulating sTNF-R type II level and survival for AIDS patients.

Authors:  F Ajello; R La Licata; M Lodato; F Vitale; F Bonura; R Valenti; M Bruno; N Romano
Journal:  Eur J Epidemiol       Date:  2000-03       Impact factor: 8.082

5.  Increased serum levels of soluble tumor necrosis factor receptors (sTNF-Rs) in children and adolescents with vertically and horizontally transmitted HIV infection.

Authors:  M Weiss; M Martignoni; T Petropoulou; B Sölder; B H Belohradsky
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

6.  Tumor necrosis factor alpha (TNF-alpha) and sepsis: evidence for a role in host defense.

Authors:  O Rigato; S Ujvari; A Castelo; R Salomão
Journal:  Infection       Date:  1996 Jul-Aug       Impact factor: 3.553

7.  Detection of anti-neutrophil cytoplasmic antibodies after acute Plasmodium falciparum malaria.

Authors:  C Wenisch; H Wenisch; H C Bankl; M Exner; W Graninger; S Looareesuwan; H Rumpold
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

8.  Comparative study of brain CD8+ T cells induced by sporozoites and those induced by blood-stage Plasmodium berghei ANKA involved in the development of cerebral malaria.

Authors:  Sébastien Bagot; Fatima Nogueira; Alexis Collette; Virgilio do Rosario; François Lemonier; Pierre-André Cazenave; Sylviane Pied
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

9.  Cytokine (IL-8, IL-6, TNF-alpha) and soluble TNF receptor-I release from human peripheral blood mononuclear cells after respiratory syncytial virus infection.

Authors:  R Arnold; B König; H Galatti; H Werchau; W König
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

10.  Immunological markers of childhood fevers in an area of intense and perennial malaria transmission.

Authors:  N Hurt; M Thein; T Smith; G Bordmann; H Gallati; N Drees; M Tanner; N Weiss
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.